Vis børsmeldingen
Total revenues reached NOK 29.8 million, an increase of 24% year-over-year,
driven by robust performance across both Biomanufacturing and Molecular Tools
segments. A significant milestone following the end of the quarter was the
signing of an exclusive European partnership agreement with Brenntag, expanding
ArcticZymes’ reach in the biomanufacturing market for advanced therapies.
Key Financials (Q3 and 9M 2025)
· Total revenue: NOK 29.8 million, up 24% from NOK 24.1 million in Q3 2024.
First nine months (9M) 2025 total revenue reached NOK 83.6 million, up 2% from
NOK 81.7 million in 9M 2024.
· Sales revenue: NOK 28.5 million, up 22% from NOK 23.3 million in Q3 2024.
· Year-to-date sales totalled NOK 78.5 million, down 1.6% compared to NOK 79.8
million in the same period of 2024.
· EBITDA: Improved to NOK 3.5 million (Q3 2024: NOK -2.3 million), reflecting
strong operational execution and cost discipline. Year-to-date EBITDA rose 42 %
to NOK 3.7 million (9M 2024: NOK 2.6 million).
· Cash flow: Cash position strengthened, with net cash flow from operations of
NOK 7.8 million in Q3 and NOK 17.2 million year-to-date (9M 2024: NOK 3.2
million), bringing total cash holdings to NOK 182.3 million and an additional
NOK 76.0 million held in low-risk, liquid interest-bearing funds.
Business Segment highlights
· Molecular Tools: Revenues of NOK 15.4 million, up 45% from NOK 10.6 million
in Q3 2024. Growth was primarily driven by renewed orders from a key account,
but other accounts contributed to the growth as well.
· Biomanufacturing: Sales of NOK 13.1 million, up 2% versus Q3 2024 (Q3 2024:
NOK 12.8 million), with 23% year-to-date growth versus 2024.
· GMP-grade products grew 173% quarter-on-quarter, now representing 26% of
Biomanufacturing sales, validating our GMP product strategy and supporting
customers as they advance into later stages of drug development.
Events After the End of the Quarter
· ArcticZymes has signed an exclusive distribution agreement with Brenntag for
the Salt Active Nucleases (SAN) in Europe.
· Brenntag, a global market leader in chemical and ingredients distribution
with a vast European network, brings strong capabilities and reach across the
life sciences and biopharmaceutical sectors
· Brenntag is appointed as the sole distributor of ArcticZymes nucleases in
Europe and will offer only ArcticZymes nucleases, ensuring full exclusivity on
both sides
· The partnership will expand ArcticZymes’ market reach, accelerate customer
access, and strengthen its position in key bioprocessing and biomanufacturing
segments.
· By leveraging Brenntag’s commercial infrastructure, technical expertise, and
established customer relationships, ArcticZymes aims to enhance market
penetration and drive long-term growth in Europe
· ArcticZymes will continue to sell SAN directly to customers in Europe,
complementing Brenntag’s distribution activities to ensure broad market
coverage, customer support and feedback
CEO Commentary
“Q3 reflects continued execution of our customer-centric strategy and another
solid quarter of progress across both Biomanufacturing and Molecular Tools,”
said Michael Akoh, CEO of ArcticZymes Technologies. “We delivered strong topline
growth and improved profitability, underpinned by robust demand for our GMP
-grade products and a notable growth recovery in the Molecular Tools segment.”
“Our new partnership with Brenntag marks an important milestone in strengthening
our European presence within biomanufacturing,” Akoh continued. “It underscores
the successful execution of our channel strategy - extending our market reach
and deepening partnerships with customers as we position ArcticZymes for long
-term, sustainable growth.”
Outlook
· Continued long term sales momentum supported by increasing adoption of GMP
-grade products, CDMO platform integration and orders from a key Molecular Tools
account.
· Enhanced European market access through the new Brenntag partnership,
expanding reach within biomanufacturing.
· Ongoing enzyme application expansion into new areas such as metagenomics,
driving long-term growth potential of the current enzyme portfolio
-Ends-
Presentation and Webcast
The Company will host a virtual Q3 and 9M 2025 presentation for investors,
analysts and media at 8:30 CET on Thursday, November 6, 2025.
The presentation will be given by CEO, Michael Akoh, CFO, Børge Sørvoll and CCO
Paul Blackburn.
The presentation can be followed as a live webcast from Hegnar TV on
https://channel.royalcast.com/landingpage/hegnarmedia/20251106_5/ or
www.arcticzymes.com. It will be possible to post questions through the webcast
console.
The report for Q3 and 9M 2025 will be available on www.newsweb.no and on the
company’s homepage www.arcticzymes.com from 07.00 CET on November 6, 2025.
For more information, please contact:
ArcticZymes Technologies ASA
CEO, Michael B. Akoh
Tel:
CFO, Børge
+46 (0)
Sørvoll
70 262
37 15
Tel:+47
952
90187
ir@arcticzymes.com
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.
Listed on the Oslo Stock Exchange since 2005. Its headquarters are based in
Tromsø, Norway, at the SIVA Science Park.
ArcticZymes Technologies’ IP and capabilities are protected via a large
portfolio of patents.
For more information, please visit the website: www.arcticzymes.com
Kilde
